The Marketing Declaration of The First JAK inhibitor made in China

This week, in the Chinese pharma market, Humanwell Healthcare's first generic drug of oxycodone hydrochloride sustained release tablets were approved for marketing; Zelgen Biopharmaceuticals' Jaktinib, the first JAK inhibitor made in China, was declared for marketing, and LEGN.US' Cilta-cel, a BCMA CAR-T cell therapy, was approved in Japan. In terms of R&D, Eisai and Biogen announced positive results from the Phase III trial of Lecanemab to treat Alzheimer's disease (AD).  More pharma news of this week worthy of attention covers topics on drug review, R&D, business, and policy. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com